Meropenem has been approved by the Food and Drug Administration (FDA) for the treatment of abdominal infections in infants less than 3 months old.
U.S. Food and Drug Administration approves Viberzi (eluxadoline) and Xifaxan (rifaximin).
A new RAND Corporation Study has shown that patients are more likely to be prescribed a broad-spectrum antibiotic for an acute respiratory infection by a doctor on a telephone or live video than face-to-face for the same illness.
Study shows it helped a minority of patients, and experts say this approach has promise.
The combination of entecavir and birinapant eradicated the hepatitis B virus in preclinical trials.
Ledipasvir and sofosbuvir with or without ribavirin is effective and safe for treating chronic genotype 1 hepatitis C virus infections.
Simeprevir and sofosbuvir had higher rates of SVR for patients with hepatitis C and compensated cirrhosis.
Treatment with inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) may reduce the risk of death from pneumonia and other causes although they are associated with an increased incidence of pneumonia.